FilingSEC EDGAR8-K
Cartesian Therapeutics Reports Positive Phase 2 Retreatment Data for Descartes-08
· SEC accepted
StagePhase 2
Filing content
The company reported positive retreatment data for Descartes-08 in myasthenia gravis patients, with Phase 3 topline results expected in Q1 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…